cagrilintide-semaglutide Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study FDA panel narrowly backs evidence:B BPC-157 Therapy Program:BPC Injection Therapy

cagrilintide-semaglutide Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study FDA panel narrowly backs evidence:B BPC-157 Therapy Program:BPC Injection Therapy

FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

Please consult your doctor and discuss all your queries related to any disease, medicine or usage

evidence:B

BPC-157 Therapy Program:BPC Injection Therapy

Cognitive Enhancement Studies Cognitive improvement studies in 28-month-old mice (equivalent to elderly humans) using 10 mg/kg body weight administered 5x per week for 3 weeks demonstrated: Significantly faster escape hole finding in Box Maze tests (trials 4 and 5) Evidence of decreased brain inflammation Increased histone deacetylase 2 labeling indicating epigenetic pathway activation Preliminary reversal of age-related cognitive impairment Pain and Anxiety Modulation Anti-pain effects in mice at 0.5 mg/kg showed efficacy comparable to cimetidine’s human analgesic effects, affecting 7 anti-pain genes (increased) and 2 genes (decreased), with upregulated opioid receptors and related pain-modulating pathways